You are on page 1of 2

INTRODUCTION

Cancer is a major public health burden in both developed and developing countries. It
was estimated that there were 10.9 million new cases, 6.7 million deaths, and 24.6
million per-sons living with cancer around the world in 2002. Cancer is the second
leading cause of death in the United States, where one in four deaths is due to cancer.
Plants have long been used in the treatment of cancer. The National Cancer Institute
collected about 35,000 plant samples from 20 countries and has screened around
114,000 extracts for anticancer activity. Of the 92 anticancer drugs commercially
available prior to 1983 in the US and among worldwide approved anticancer drugs
between 1983 and 1994, 60% are of natural origin. [1]
Growth of solid tumours in both the primary and metastatic sites depends on
angiogenesis, the formation of new blood vessels, to nourish the tumour. In
pioneering work by Folkman, cancer cells implanted in vascular sites in animals grew
rapidly and formed large tumours. In contrast, cells implanted in vascular sites were
unable to form tumour masses 1 to 2 mm in size. This work led Folkman to
hypothesize that angiogenesis was obligatory for tumour growth. [2]
It is generally accepted today that tumour growth is angiogenesis-dependent and that
every

increment of tumour growth requires an increment of vascular growth.

Tumours lacking angiogenesis remain dormant indefinitely and rapid logarithmic
growth follows the acquisition of blood supply. The tumour angiogenic switch seems
to be activated when the balance of angiogenic inhibitors to stimulators is shifted
toward a proangiogenic milieu. [3]
Tumour angiogenesis has become an intensely investigated area over the last decade
because it is an essential component of the growth and spread of cancer and is
therefore potentially an important therapeutic target. [4]

Dept Of Pharmacology, KCP,Banglore-64

Page 1

The use of medicinal plants in therapeutics or as dietary supplements goes back beyond recorded history. Traditional herbal medicine has long been recognized as a potential source for discovering such agents. therapeutic efficacy. The popularity of herbal medicines is connected with their easy access.INTRODUCTION Now-a-days. Therefore the present study was initiated with the objective of investigating whether the saponins of Momordica Cymbalaria is having antiangiogenic property or not. and it is not yet screened for its antiangiogenic activity. a key feature that is useful in angiogenesis inhibition. Combination of antiangiogenic agents together. have shown promising results presenting this way a new window to look at the possibilities for cancer cure accomplishment. The success of antiangiogenic therapy for cancer treatment has led to an explosion in the research for antiangiogenic agents. [5] Momordica charantia. Indeed. but has increased substantially in the last decades. and assumed absence of toxic side effects. Different antiangiogenic agents attack different steps in the process by intervening with the function and expression of various angiogenic molecules. Anti-angiogenic therapy is the most investigated field in anti-cancer research. family of Cucurbitaceae. Momordica Cymbalaria which belongs to the same family was proven for its antioxidant activity [7] . relatively low cost. Many natural products tend to have high level of antioxidant property.Banglore-64 Page 2 . Dept Of Pharmacology. many herbs and phytochemicals have been shown to have antiangiogenic activities both invitro and invivo. KCP. Angiogenesis process is very important for tumour growth and in addition for tumour metastasis. is having invivo antitumour activity [6] . such as chemotherapy. antioxidant activity. and/or with other types of therapies. Understanding the basic mechanisms and influencing factors will therefore help in controlling and/or inhibiting Angiogenesis.